Top in allergy/asthma: FDA OKs Xhance; acid-suppressive therapy linked with food allergy
Click Here to Manage Email Alerts
The FDA approved Xhance for the treatment of chronic rhinosinusitis without nasal polyps among patients aged 18 years and older.
Xhance (fluticasone, Optinose) uses the Exhalation Delivery System to reach areas of the nasal cavity and sinuses that other nasal sprays tend to miss, according to the manufacturer. In phase 3 trials, patients experienced 56% to 66% fewer acute exacerbations compared with placebo.
It was the top story in allergy/asthma last week.
In another top story, a study found that infants who were exposed to acid-suppressive medications had a higher risk for developing food allergy, anaphylaxis, atopic dermatitis and allergic rhinitis. The risk was highest among those who were prescribed proton pump inhibitors.
Read these and more top stories in allergy/asthma below:
FDA OKs fluticasone propionate nasal spray for chronic rhinosinusitis without nasal polyps
The FDA has approved fluticasone propionate nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients aged 18 years and older, according to an Optinose press release. Read more.
Acid-suppressive medications in infancy associated with food allergy risks
Infants who were exposed to acid-suppressive medications had increased risk for developing food allergy, according to an abstract presentation. Read more.
Vaccination delayed, avoided with dupilumab treatment
Children taking Dupixent (dupilumab; Regeneron, Sanofi) for atopic diseases received measles, mumps and rubella and varicella immunizations later than other children, according to a poster presentation. Read more.
Children with FPIES may tolerate reintroduction of reaction triggers at home
Some children with food protein-induced enterocolitis syndrome may safely reintroduce triggers into their diets at home, according to a study. Read more.
Vaccination, prophylaxis recommended for children with primary immunodeficiencies
Children with primary immunodeficiencies should receive routine inactive vaccinations and other prophylactic treatment, according to a presentation. Read more.